

Chapter 1

Robotic Assisted Laparoscopic Surgery: A Review of its Application and Impact on Pelvic Colorectal Surgery

TB Nobel¹, DS Keller^{2,3} and EM Haas^{2,3,4}

¹Department of Surgery, Icahn School of Medicine at Mount Sinai, USA

²Colorectal Surgical Associates, USA

³Houston Methodist Hospital, USA

⁴University of Texas Medical School at Houston, USA

***Corresponding Author:** Eric M Haas, Colorectal Surgical Associates; Houston Methodist Hospital; University of Texas Medical School at Houston; 6560 Fannin, Suite 1404 Houston, TX 77030, USA; Tel: (713) 790-0600; Fax: (713) 790-0616; Email: ehaasmd@houstoncolon.com

First Published **November 16, 2015**

Copyright: © 2015 Eric M Haas et al.

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source.

Abstract

Laparoscopy was a major technical advance for colorectal surgery, with great clinical and financial benefits compared to open surgery for both benign and malignant colorectal diseases. Despite proven clinical advantages, the rate of laparoscopy for pelvic colorectal surgery remains low. The technical advantages of robotic assisted laparoscopic surgery may help overcome the limitations of other minimally invasive techniques in pelvic colorectal surgery. The safety, feasibility, and comparative effectiveness has been proven compared to open and laparoscopic approaches, and specific advantages and technical applications continue to evolve. The goal of this paper is to review the history, benefits, clinical outcomes, and future direction for RALS in pelvic colorectal surgery.

Keywords

Robotics, Pelvic Surgery; Rectal Cancer; Minimally Invasive Surgery; Colorectal Surgery

Introduction

Minimally invasive colorectal surgery has valuable benefits over open procedures, including decreased post-operative pain, shorter lengths of stay, lower complication rates, and faster recovery of bowel function [1-11]. The transition to minimally invasive rectal resection has been a slower process. Initial concerns over oncologic adequacy, recurrence and survival rates, and sexual dysfunction delayed widespread acceptance compared to co-

lon cancer [12]. While the safety, feasibility, and oncologic equivalence have been proven in multiple controlled studies, approximately 50% of total colorectal cases and less than 10% of rectal cancer cases are performed through a laparoscopic approach [13-15]. A major reason for the low number of minimally invasive pelvic cases may be the technical challenges of operating deep in the confined, narrow pelvis [16,17]. Robotic assisted laparoscopic surgery (RALS) has emerged as a minimally invasive platform with specific benefits in pelvic colorectal cases. The goal of this paper is to review the history, benefits, clinical outcomes, and future direction for RALS in pelvic colorectal surgery.

History of RALS in Colorectal Surgery

In 2000, Intuitive Surgical's DaVinci robotic system was FDA-approved for intrabdominal applications in the United States. The first colorectal RALS was performed in 2001, [18]. Since that time, continued growth has been seen, from 0.8% in 2008 to over 4% in 2009 for all general surgical procedures [19,20]. In colorectal surgery specifically, an estimated 2.8% of the 130,000 annual minimally invasive procedures were performed through a robotic approach [19]. With the rapid growth of this minimally invasive platform, there has been substantial research into the outcomes and benefits of the robot for colorectal pro-

cedures.

Technical Limitations of Traditional Laparoscopy and Benefits of RALS

The anatomy of the narrow, deep pelvis results in a confined operative field that makes visualization and dissection difficult, [21,22]. Laparoscopy is limited by tremor, assistant-dependent unstable 2-dimensional optics, the inability to perform high-precision suturing, poor ergonomics, and limited dexterity of surgical instruments [23,24]. In pelvic colorectal surgery, these limitations become more relevant; dissection is limited by retraction of the rectum, crowding and clashing of instruments, and fumes in the confined spaces fogging the camera, [18,25]. These challenges can be overcome by expert technique and experience, but for widespread adoption, they are a limitation of laparoscopy in pelvic cases. The robot is well suited for surgery in confined spaces, such as the pelvis. The robot allows a 3-dimensional view, controlled by the operating surgeon, a stable retraction platform, enhanced dexterity, and an endoscopic articulated wrist that allows seven degrees of freedom. Increased precision and accuracy from the instruments allow for a still visibility of the field and gives the surgeon equal access to the both sides of the pelvis [26,27]. These technical advantages translate to clinical advantages in technically demanding pelvic surgery, which may help overcome the limitations of laparoscopy in the pelvis [28].

Outcomes of RALS in Rectal Cancer

Most reports describe consistently better outcomes with RALS than open colorectal surgery, and comparable outcomes to laparoscopic colorectal surgery with higher costs and longer operative times [23,29-43] (Table 1).

Table 1: Robotic Assisted Laparoscopic Surgery in the Literature.

Author (Year)	Type of Study	n	Operative Time, Min	Length of Stay, Days	Complications	Lymph Nodes
Delaney et al (2003)	Case-Control	6 RALS	165 (115-220)	3 (2-5)	1 (atelectasis)	—
		6 Lap	108 (74-125)	2.5 (2-7)	1 (incisional hernia)	
Baek et al (2012)	Comparative	154 RALS	285.2 ± 69.1	11.1 ± 7	30 (32.1%)	20.0 ± 9.1
		150 Lap	219.7 ± 71.2	10.8 ± 8.6	41 (27.3%)	17.4 ± 10.6
Baik et al (2008)	Randomized Control Trial	18 RTME	217.1 ± 51.6	6.9 ± 1.3	22.20%	20 ± 9.1
		18 LTME	204.3 ± 51.9	8.7 ± 1.3	5.50%	17.4 ± 10.6
Baik et al (2009)	Comparative	56 R LAR	190.1 ± 45	5.7 ± 1.1	6 (10.7%)	18.4 ± 9.2
		57 L LAR	191.1 ± 65.3	7.6 ± 3	11 (19.3%)	18.7 ± 12
D'Annibale et al (2004)	Case Series	53 RALS	240 ± 61	10 ± 4	4	17 ± 10
		53 Lap	222 ± 77	10 ± 6	9	16 ± 9
D'Annibale et al (2013)	Case Series	50 R TME	270 (240-315)	8 (7-11)	5 (10%)	16.5 ± 7.1
		50 L TME	280 (240-350)	10 (8-14)	11 (22%)	13.8 ± 6.7
Park et al (2011)	Comparative	RALS 52	232.6 (52.4)	10.4 (4.7)	10 (19.2%)	19.4 (10.2)
		Lap 123	158.1 (49.2)	9.8 (3.8)	15 (12.2%)	15.9 (10.1)
		Open 88	233.8 (59.2)	12.8 (7.1)	18 (20.5%)	18.5 (10.9)
Park et al (2013)	Comparative	40 RALS	235.5 (57.)	10.6 (4.2)	6 (15%)	12.9 (7.5)
		40 Lap	185.4 (72.8)	11.3 (3.6)	5 (12.5%)	13.3 (8.6)
Keller et al (2013)	Comparative	744 RALS	261 (253, 269)	7.46 (6.90)	35.90%	—
		17, 265 Lap	201 (198, 203)	6.13 (6.05)	29.90%	

RALS-Robotic Assisted Laparoscopic Surgery; Lap- Laparoscopic; RTME-Robotic Total Mesorectal Excision

Intra-Operative Outcomes

The majority of rectal cancer resections are still performed via an open fashion [19]. Studies comparing open versus robotic procedures have demonstrated similar intra-operative outcomes, except for longer operative time [38,44]. Yang et al reported a decrease in blood loss with RALS [42], with the reduction in blood loss stemming from improved visualization and detection of blood vessels in the narrow pelvis [45].

Peri-operative Outcomes

The majority of studies reported similar hospital length of stay between RALS and traditional multiport laparoscopy [19,32,34-37,40-42], with two studies reporting shorter length of stay for RALS [31,33]. No difference in recovery of bowel function has been shown between groups [19,30,35,37,41,42]. Post-operative complications rates have generally been found equivalent between RALS and laparoscopy [19,33-35,39-41], with two studies citing higher rates of post-operative bleeding with RALS [19,34].

Oncological Outcomes

RALS has been demonstrated safe and oncologically comparable to laparoscopic outcomes [27,30-33,37,38,40,41]. Recent studies have even reported some oncologic advantages with RALS, including a higher rate

of negative circumferential margins [33,41,46], a better TME specimen [31], a lower recurrence rate compared to laparoscopy [44].

Genitourinary Outcomes

There is an increased risk of bladder and sexual dysfunction following TME due to the anatomy, especially following radiation. Robotic TME enables better visualization of the autonomic plexus in the pelvis, leading to improved preservation of genitourinary, erectile, and voiding function [16]. Kim et al demonstrated patients who underwent robotic TME for rectal cancer has faster recovery than those who underwent laparoscopic procedures [46]. Other studies support a lower overall incidence of erectile dysfunction with RALS [33,41].

Learning Curve of RALS

There is always a learning curve with new technology, and the learning curve of RALS has been well described. Bokhari et al evaluated performance across several types of pelvic robotic procedures, finding a 3 phase learning curve: the initial learning curve which spanned 15 cases; a plateau phase that demonstrated increased competence with use; and mastery of more challenging cases achieved after 25 cases [47]. Several other studies support the multiphasic learning curve, with improvement first noted after 9-15 cases, mastery and ability to handle more challenging cases after 20-25 cases, and more challenging cases with

expected increased overall operative time thereafter [47-50]. Robotic pelvic surgery demonstrates a faster learning curve than laparoscopic surgery making it a more effective method of practice.

Future Direction of Pelvic Robot Use: Robotic Transanal TME

Robotic assisted transanal surgery (RATS) is a natural evolution of transanal minimally invasive surgery (TAMIS), a hybrid of transanal endoscopic microsurgery and single incision laparoscopic surgery [51]. RATS was originally described in a cadaveric model in 2011 [52], with promising early results in clinical application [53]. In 2013, the technology was pushed to TAMIS robotic TME, with promising results reported by Atallah et al in their pilot study [54]. The patients had a 6.7% anastomotic leak rate and 85% had “near complete” or “complete” pathological specimen grading [54]. Two small subsequent studies described the patient experience with robotic-assisted TME, reporting “complete” pathological specimen grading and negative margins for all patients in these series (Table 2) [55,56].

Table 2: Robotic-Assisted Transanal TME.

Author (Year)	n	Operative Time (minutes)	Blood Loss (milliliters)	Length of Stay (days)	Negative Margins	Pathologic Grade of TME Specimen	Complications
Atallah et al (2014)	4	376 (140-409)*	200 (50-300)	4.3 (4-5)	100% (4/4)	100% complete (4/4)	3/4; pulmonary embolism, hematoma, dehydration
Gomez Ruiz et al (2015)	5	398 ± 88**	Not Reported	6 ± 1	100% (5/5)	100% complete (5/5)	1/5; anastomotic leak

A Word on Cost Effectiveness of Robotics in Colorectal Surgery

Robotic surgery is more expensive than laparoscopy, which has raised concern regarding utilization. Pai et al attributed the higher costs to fixed costs of purchase and maintenance of equipment, consumables, and increased operative time, but argue that cost must be weighed against benefits including shorter length of stay and oncologic outcomes [16]. It is feasible that with increased experience, operative time will be shorter and higher case volumes will be possible, potentially leading to cost effectiveness. There are clear technical benefits to this approach, which indicate that further research on cost effectiveness is warranted. There should also be a paradigm shift in the cost comparison across platforms. Currently, most reports compare costs between laparoscopy and RALS [19,29,34,57]. However, RALS is a platform meant

to increase overall use of minimally invasive surgery, not convert laparoscopic users to robotics. Therefore, the cost comparison should be between open colorectal surgery and RALS. Studies comparing these platforms have demonstrated faster recovery, reduced postoperative pain, shorter length of stays, lower complications, and lower mortality rates with RALS, resulting in an overall cost benefit for RALS than open colorectal surgery [20].

**Figure 1: Robotic Set Up.**




Figure 2: Internal and External Working Views.



Figure 3: Console Surgeon View.

Conclusions

Pelvic robotic colorectal surgery is safe and effective. Current studies demonstrate equivalent outcome to laparoscopic surgery, with certain RALS advantages over traditional laparoscopy. Data from the ROLARR trial [58] will help confirm these benefits and further utilization of this minimally invasive platform in pelvic colorectal surgery.

References

1. Nelson H, Sargent DJ, COST Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer. *N Engl J Med.* 2004; 350: 2050-2059.
2. Bonjer HJ, Hop WC, Nelson H, Sargent DJ, Lacy AM, et al. Laparoscopically assisted vs open colectomy for colon cancer: a meta-analysis. *Arch Surg.* 2007; 142: 298-303.
3. Color II Study Group, Buunen M, Bonjer HJ, Hop WC, Haglind E, et al. COLOR II. A randomized clinical trial comparing laparoscopic and open surgery for rectal cancer. *Dan Med Bull.* 2009; 56: 89-91.
4. Green BL, Marshall HC, Collinson F, Quirke P, Guillou P, et al. Long-term follow-up of the Medical Research Council CLASICC trial of conven-

- tional versus laparoscopically assisted resection in colorectal cancer. *Br J Surg.* 2013; 100: 75-82.
5. Guillou PJ, Quirke P, Thorpe H, Walker J, Jayne DG, et al. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. *Lancet.* 2005; 365: 1718-1726.
 6. Jayne DG, Guillou PJ, Thorpe H et al. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. *J Clin Oncol.* 2007;25:3061-3068.
 7. Jayne DG, Thorpe HC, Copeland J, Quirke P, Brown JM, Guillou PJ. Five-year follow-up of the Medical Research Council CLASICC trial of laparoscopically assisted versus open surgery for colorectal cancer. *Br J Surg.* 2010; 97: 1638-1645.
 8. Kuhry E, Schwenk W, Gaupset R, Romild U, Bonjer J. Long-term outcome of laparoscopic surgery for colorectal cancer: a cochrane systematic review of randomised controlled trials. *Cancer Treat Rev.* 2008; 34: 498-504.
 9. Lacy AM, García-Valdecasas JC, Delgado S, Castells A, Taurá P, et al. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. *Lancet.* 2002; 359: 2224-2229.
 10. Martijn HGM van der Pas, Eva Haglind, Miguel A Cuesta, Alois Fürst, Antonio M Lacy, et al. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. *Lancet Oncol.* 2013; 14: 210-218.
 11. Veldkamp R, Kuhry E, Hop WC, Jeekel J, Kazemier G., et al. Laparoscopic surgery versus open surgery for colon cancer: short-term outcomes of a randomised trial. *Lancet Oncol.* 2005; 6: 477-484.
 12. Champagne BJ, Makhija R. Minimally invasive surgery for rectal cancer: are we there yet? *World J Gastroenterol.* 2011; 17: 862-866.
 13. Carmichael JC, Masoomi H, Mills S, Stamos MJ, Nguyen NT. Utilization of laparoscopy in colorectal surgery for cancer at academic medical centers: does site of surgery affect rate of laparoscopy? *Am Surg.* 2011; 77: 1300-1304.
 14. Fox J, Gross CP, Longo W, Reddy V. Laparoscopic colectomy for the treatment of cancer has been widely adopted in the United States. *Dis Colon Rectum.* 2012; 55: 501-508.

15. Surgical Care and Outcomes Assessment Program (SCOAP) Collaborative, Kwon S, Billingham R, Farrokhi E, Florence M, et al. Adoption of laparoscopy for elective colorectal resection: a report from the Surgical Care and Outcomes Assessment Program. *J Am Coll Surg.* 2012; 214: 909-918.
16. Pai A, Melich G, Marecik SJ, Park JJ, Prasad LM. Current status of robotic surgery for rectal cancer: A bird's eye view. *J Minim Access Surg.* 2015; 11: 29-34.
17. Row D, Weiser MR. An update on laparoscopic resection for rectal cancer. *Cancer Control.* 2010; 17: 16-24.
18. Ballantyne GH, Merola P, Weber A, Wasielewski A. Robotic solutions to the pitfalls of laparoscopic colectomy. *Osp Ital Chir.* 2001; 7: 405-412.
19. Halabi WJ, Kang CY, Jafari MD, Nguyen VQ, Carmichael JC, et al. Robotic-assisted colorectal surgery in the United States: a nationwide analysis of trends and outcomes. *World J Surg.* 2013; 37: 2782-2790.
20. Salman M, Bell T, Martin J, Bhuvu K, Grim R, Ahuja V. Use, cost, complications, and mortality of robotic versus nonrobotic general surgery procedures based on a nationwide database. *Am Surg.* 2013; 79: 553-560.
21. Lee SW. Laparoscopic Procedures for colon and rectal cancer surgery. *Clin Colon Rectum.* 2003; 46: 1633-1639.
22. Kim JY, Kim YW, Kim NK, Hur H, Lee K, et al. Pelvic anatomy as a factor in laparoscopic rectal surgery: a prospective study. *Surg Laparosc Endosc Percutan Tech.* 2011; 21: 334-339.
23. Delaney CP, Lynch AC, Senagore AJ, Fazio VW. Comparison of robotically performed and traditional laparoscopic colorectal surgery. *Dis Colon Rectum.* 2003; 46: 1633-1639.
24. Choi DJ, Kim SH, Lee PJ, Kim J, Woo SU. Single-stage totally robotic dissection for rectal cancer surgery: technique and short-term outcome in 50 consecutive patients. *Dis Colon Rectum.* 2009; 52: 1824-1830.
25. Cecil TD, Taffinder N, Gudgeon AM. A personal view on laparoscopic rectal cancer surgery. *Colorectal Dis.* 2006; 8: 30-32.
26. Baek SJ, Kim CH, Cho MS, Bae SU, Hur H, et al. Robotic surgery for rectal cancer can overcome difficulties associated with pelvic anatomy. *Surg Endosc.* 2014
27. deSouza AL, Prasad LM, Marecik SJ, Blumetti J, Park JJ, et al. Total mesorectal excision for rectal

- cancer: the potential advantage of robotic assistance. *Dis Colon Rectum*. 2010; 53: 1611-1617.
28. Scarpinata R, Aly EH. Does robotic rectal cancer surgery offer improved early postoperative outcomes? *Dis Colon Rectum*. 2013; 56: 253-262.
 29. Baek SJ, Kim SH, Cho JS, Shin JW, Kim J. Robotic versus conventional laparoscopic surgery for rectal cancer: a cost analysis from a single institute in Korea. *World J Surg*. 2012; 36: 2722-2729.
 30. Baik SH, Ko YT, Kang CM, Lee WJ, Kim NK, et al. Robotic tumor-specific mesorectal excision of rectal cancer: short-term outcome of a pilot randomized trial. *Surg Endosc*. 2008; 22: 1601-1608.
 31. Baik SH, Kwon HY, Kim JS, Hur H, Sohn SK, et al. Robotic versus laparoscopic low anterior resection of rectal cancer: short-term outcome of a prospective comparative study. *Ann Surg Oncol*. 2009; 16: 1480-1487.
 32. D'Annibale A, Morpurgo E, Fiscon V, Trevisan P, Sovernigo G, et al. Robotic and laparoscopic surgery for treatment of colorectal diseases. *Dis Colon Rectum*. 2004; 47: 2162-2168.
 33. D'Annibale A, Pernazza G, Monsellato I, Pende V, Lucandri G, et al. Total mesorectal excision: a comparison of oncological and functional outcomes between robotic and laparoscopic surgery for rectal cancer. *Surg Endosc*. 2013; 27: 1887-1895.
 34. Keller DS, Senagore AJ, Lawrence JK, Champagne BJ, Delaney CP. Comparative effectiveness of laparoscopic versus robot-assisted colorectal resection. *Surg Endosc*. 2014; 28: 212-221.
 35. Lin S, Jiang HG, Chen ZH, Zhou SY, Liu XS, Yu JR. Meta-analysis of robotic and laparoscopic surgery for treatment of rectal cancer. *World J Gastroenterol*. 2011; 17: 5214-5220.
 36. Memon S, Heriot AG, Murphy DG, Bressel M, Lynch AC. Robotic versus Laparoscopic Proctectomy for Rectal Cancer: A Meta-analysis. *Ann Surg Oncol*. 2012;19: 2095-2101.
 37. Ortiz-Oshiro E, Sanchez-Egido I, Moreno-Sierra J, Perez CF, Diaz JS, Fernandez-Represa JA. Robotic assistance may reduce conversion to open in rectal carcinoma laparoscopic surgery: systematic review and meta-analysis. *Int J Med Robot*. 2012; 8: 360-370.
 38. Park JS, Choi GS, Lim KH, Jang YS, Jun SH. S052: a comparison of robot-assisted, laparoscopic, and open surgery in the treatment of rectal cancer. *Surg Endosc*. 2011; 25: 240-248.
 39. Park SY, Choi GS, Park JS, Kim HJ, Ryuk JP. Short-term clinical outcome of robot-assisted in-

- tersphincteric resection for low rectal cancer: a retrospective comparison with conventional laparoscopy. *Surg Endosc.* 2013; 27: 48-55.
40. Trastulli S, Farinella E, Cirocchi R, Cavaliere D, Avenia N, et al. Robotic resection compared with laparoscopic rectal resection for cancer: systematic review and meta-analysis of short-term outcome. *Colorectal Dis.* 2012; 14: 134-156.
 41. Xiong B, Ma L, Huang W, Zhao Q, Cheng Y, Liu J. Robotic Versus Laparoscopic Total Mesorectal Excision for Rectal Cancer: a Meta-analysis of Eight Studies. *J Gastrointest Surg.* 2015; 19: 516-526.
 42. Yang Y, Wang F, Zhang P, Shi C, Zou Y, et al. Robot-Assisted Versus Conventional Laparoscopic Surgery for Colorectal Disease, Focusing on Rectal Cancer: A Meta-analysis. *Ann Surg Oncol.* 2012; 19: 3727-3736.
 43. Young M, Pigazzi A. Total mesorectal excision: open, laparoscopic or robotic. *Recent Results Cancer Res.* 2014; 203: 47-55.
 44. Ghezzi TL, Luca F, Valvo M, Corleta OC, Zuccaro M, et al. Robotic versus open total mesorectal excision for rectal cancer: comparative study of short and long-term outcomes. *Eur J Surg Oncol.* 2014; 40: 1072-1079.
 45. Popescu I, Vasilescu C, Tomulescu V, Vasile S, Sgarbura O. The minimally invasive approach, laparoscopic and robotic, in rectal resection for cancer. A single center experience. *Acta Chir Iugosl.* 2010; 57: 29-35.
 46. Kim JY, Kim NK, Lee KY, Hur H, Min BS, Kim JH. A comparative study of voiding and sexual function after total mesorectal excision with autonomic nerve preservation for rectal cancer: laparoscopic versus robotic surgery. *Ann Surg Oncol.* 2012; 19: 2485-2493.
 47. Bokhari MB, Patel CB, Ramos-Valadez DI, Ragupathi M, Haas EM. Learning curve for robotic-assisted laparoscopic colorectal surgery. *Surg Endosc.* 2011; 25: 855-860.
 48. Jimenez-Rodriguez RM, Diaz-Pavon JM, de la Portilla de Juan F, Prendes-Sillero E, Dussort HC, Padillo J. Learning curve for robotic-assisted laparoscopic rectal cancer surgery. *Int J Colorectal Dis.* 2013; 28: 815-821.
 49. Kim HJ, Choi GS, Park JS, Park SY. Multidimensional Analysis of the Learning Curve for Robotic Total Mesorectal Excision for Rectal Cancer: Lessons From a Single Surgeon's Experience. *Dis Colon Rectum.* 2014; 57: 1066-1074.
 50. Sng KK, Hara M, Shin JW, Yoo BE, Yang KS, et al.

The multiphasic learning curve for robot-assisted rectal surgery. *Surg Endosc.* 2013; 27: 3297-3307.

51. Atallah S, Albert M, Larach S. Transanal minimally invasive surgery: a giant leap forward. *Surg Endosc.* 2010; 24: 2200-2205.
52. Atallah SB, Albert MR, deBeche-Adams TH, Larach SW. Robotic TransAnal Minimally Invasive Surgery in a cadaveric model. *Tech Coloproctol.* 2011; 15: 461-464.
53. Atallah S, Parra-Davila E, DeBeche-Adams T, Albert M, Larach S. Excision of a rectal neoplasm using robotic transanal surgery (RTS): a description of the technique. *Tech Coloproctol.* 2012; 16: 389-392.
54. Atallah S, Martin-Perez B, Pinan J, Quinteros F, Schoonyoung H, et al. Robotic transanal total mesorectal excision: a pilot study. *Tech Coloproctol.* 2014; 18: 1047-1053.
55. Atallah S, Martin-Perez B, Albert M et al. Transanal minimally invasive surgery for total mesorectal excision (TAMIS-TME): results and experience with the first 20 patients undergoing curative-intent rectal cancer surgery at a single institution. *Tech Coloproctol.* 2014; 18: 473-480.
56. Gómez Ruiz M1, Parra IM, Palazuelos CM, Martín JA, Fernández CC, et al. Robotic-assisted lapa-

roscopic transanal total mesorectal excision for rectal cancer: a prospective pilot study. *Dis Colon Rectum.* 2015; 58: 145-153.

57. Tyler JA, Fox JP, Desai MM, Perry WB, Glasgow SC. Outcomes and costs associated with robotic colectomy in the minimally invasive era. *Dis Colon Rectum.* 2013; 56: 458-466.
58. Collinson FJ, Jayne DG, Pigazzi A, Tsang C, Barrie JM, et al. An international, multicentre, prospective, randomised, controlled, unblinded, parallel-group trial of robotic-assisted versus standard laparoscopic surgery for the curative treatment of rectal cancer. *Int J Colorectal Dis.* 2012; 27: 233-241.